Drug intelligence / Profile preview

STP-B

Development stage: Preclinical
Lead developer: Step Pharma
Modality: Small Molecules
Administration: Oral

Overview

STP-B is a small molecule inhibitor of cytidine triphosphate synthase 1 (CTPS1) currently under investigation for its potential in treating acute myeloid leukemia (AML). Its mechanism of action involves disrupting nucleotide metabolism by drastically decreasing intracellular CTP levels, which in turn promotes myeloid differentiation, specifically macrophage M1 polarization. Furthermore, STP-B stimulates IFN-α signaling by inhibiting CTPS1-mediated deamidation of IRF3 and histone H1, leading to enhanced expression of IFN-stimulatory genes and increased DNA damage. These multifaceted effects contribute to its potent anti-AML activity and immune-stimulatory properties, making it a promising leukemia-ablating agent.

Targets

CTPS1 (Cytidine triphosphate synthase 1)

Beyond the preview

Go deeper on STP-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STP-B.

Explore the full profile